RGRX : Summary for REGENERX BIOPHARM IN - Yahoo Finance

U.S. Markets open in 4 hrs 36 mins

RegeneRx Biopharmaceuticals, Inc. (RGRX)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.29+0.01 (+2.11%)
At close: 2:39PM EDT
People also watch
LCARPRTXAOLSSNGXOXIS
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.28
Open0.29
Bid0.00 x
Ask0.00 x
Day's Range0.28 - 0.29
52 Week Range0.25 - 0.75
Volume6,000
Avg. Volume22,532
Market Cap30.96M
Beta1.89
PE Ratio (TTM)144.95
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • RegeneRx Biopharmaceuticals, Inc. :RGRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 31, 2017
    Capital Cube26 days ago

    RegeneRx Biopharmaceuticals, Inc. :RGRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 31, 2017

    Categories: Yahoo Finance Get free summary analysis RegeneRx Biopharmaceuticals, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of RegeneRx Biopharmaceuticals, Inc. – MediWound Ltd., XOMA Corporation, Sevion Therapeutics, Inc., Akorn, Inc., Rigel Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc. Class A, Mateon Therapeutics, Inc. and Capstone Therapeutics Corp. ... Read more (Read more...)

  • PR Newswirelast month

    RegeneRx Releases Annual Letter to Shareholders

    ROCKVILLE, Md., March 13, 2017 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has released its annual letter to shareholders. The 2017 letter is focused on updating shareholders on the Company's product development and commercial partnerships, anticipated clinical milestones, fund-raising, and other operational plans over the next twelve months. Any statements in this shareholder letter that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995.

  • PR Newswire2 months ago

    RegeneRx Licensee Receives FDA Permission to Conduct a Phase 3 Trial of RGN-137 for Epidermolysis Bullosa in U.S.

    ROCKVILLE, Md., Feb. 27, 2017 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its licensee for RGN-137, GtreeBNT Co., Ltd., received a positive response from the U.S. FDA for its Phase 3 clinical trial design for RGN-137 to treat epidermolysis bullosa ("EB"). EB is a rare inherited skin disease that is caused by genetic defects in anchoring between the epidermis and dermis, resulting in skin fragility.